Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
An update from NetScientific ( (GB:EMVC) ) is now available.
PDS Biotechnology, a portfolio company of EMV Capital, has announced the planned initiation of the VERSATILE-003 Phase 3 clinical trial for the treatment of HPV16-positive head and neck squamous cell carcinoma (HNSCC) with its Versamune® HPV plus pembrolizumab combination. This trial, anticipated to begin in the first quarter of 2025, follows FDA clearance and aims to address the needs of the growing HPV16-positive patient subgroup. PDS Biotech’s advancements in immunotherapy and the use of a companion diagnostic for confirming HPV16 status highlight its commitment to developing targeted cancer treatments, potentially improving outcomes for patients and enhancing its position in the oncology sector.
More about NetScientific
EMV Capital plc, formerly known as NetScientific plc, is a deep tech and life sciences venture capital investment group headquartered in London. The company focuses on generating superior returns for investors by investing in high-growth, early-stage companies within fast-growing sectors and technologies. EMV Capital holds direct equity stakes and carried interest in its portfolio companies, offering extensive growth and value creation through its proactive management approach.
YTD Price Performance: 0.82%
Average Trading Volume: 41,108
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £13.47M
For an in-depth examination of EMVC stock, go to TipRanks’ Stock Analysis page.